MarketN-Ethylpentylone
Company Profile

N-Ethylpentylone

N-Ethylpentylone is a substituted cathinone and stimulant drug which was developed in the 1960s.

Adverse effects
N-Ethylpentylone has been reported to cause lethal heart palpitations and hallucinations. It has been linked to a number of overdose deaths and has increasingly been mis-sold as MDMA. == Pharmacology ==
Pharmacology
N-Ethylpentylone is primarily a mixed norepinephrine reuptake inhibitor and dopamine reuptake inhibitor. It binds to transporters with IC50 values of 37 nM (dopamine transporter), 105 nM (norepinephrine transporter) and 383 nM (serotonin transporter). The methylenedioxy ring-substitution provides a higher potency at inhibiting serotonin reuptake than its analogue N-ethylpentedrone. N-Ethylpentylone is also a low-potency serotonin 5-HT2A receptor agonist, with an of 5,200nM. In vivo studies in mice demonstrated that acute intraperitoneal administration of N-ethylpentylone induced an increase in locomotor activity, anxiolytic effects but also an aggressive behaviour as well as social exploration deficits. Repeated exposure to N-ethylpentylone induced hyperthermia, anorexia and rewarding effects. During withdrawal after repeated administration, depression-like symptoms, hyperlocomotion, and a decrease of social exploration were observed. ==Society and culture==
Society and culture
Legal status • In the United States, N-ethylpentylone is a Schedule I controlled substance since June 2018. • In Taiwan, N-ethylpentylone is a controlled substance under Taiwan's Controlled Drugs Act since Dec 2017. • In the Netherlands it has been added to the Opium Law on July 1 2025. == See also ==
tickerdossier.comtickerdossier.substack.com